However, antagonism of GPR172A is anticonvulsant; conversely, activation is used to produce an animal model of absence seizures [69] making higher γ-hydroxybutyrate unlikely to be involved in a better anticonvulsant response to the KD. The gene discussed is SLC52A2; the disease is juvenile absence epilepsy.